Background: In the elderly, impaired cognition may weaken medication adherence
Introduction
Medication adherence is vital for long-term healthcare expenditure. 1, 2 Low medication adherence may account for up to $300 billion of annual healthcare costs in the United States. 3 It has been estimated that up to 50% of patients do not adhere to prescribed medications, defined as taking fewer doses than prescribed or discontinuing treatment. [4] [5] [6] [7] Low medication adherence may compromise the effectiveness of treatment for cardiovascular conditions, such as hypertension, 8, 9 dyslipidaemia 10,11 and hyperglycemia. 12, 13 However, a systematic review of randomised controlled trials of medication adherence interventions concluded that most strategies aimed at improving medication adherence have not been successful in improving adherence and clinical outcomes for cardiovascular diseases (CVD) and associated risk factors. 14 
This highlights the need to identify risk factors contributing to
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low medication adherence and how low adherence affects CVD risk among high-risk populations. 15 Older adults constitute a high-risk population for poor medication adherence; as the population ages, chronic coexisting conditions coupled with decreased cognitive functioning might lead to decreased adherence. 7, 16, 17 A recent systematic review of 15 studies concluded that individuals with cognitive impairment had lower rates of medication adherence compared to those without cognitive impairment. 17 Furthermore, the Cohort Study of Medication Adherence among Older Adults (CoSMO), a prospective cohort study of 2194 older adults with hypertension, examined the barriers to antihypertensive adherence and clinical outcomes. 16 Participants with low compared with high cognitive functioning were 2.71 times more likely to have low medication adherence and 1.20 times more likely to have uncontrolled blood pressure. 16 However, a large gap of knowledge exists regarding risk factors for poor medication adherence and the clinical implications of medication non-adherence on chronic diseases in older adults, particularly those at risk for cognitive decline. 7 The objectives of the present study were to: (i) examine risk factors (demographic, socio-economic, lifestyle and cognitive factors) associated with medication adherence; and (ii) study the cross-sectional associations between medication adherence and levels of CVD risk factors among participants with hypertension, dyslipidaemia and diabetes in a sample of older adult participants enrolled in a large community-based cohort. Our hypothesis was that low medication adherence would be common and associated with adverse CVD risk factor profiles.
Methods

Study sample
Framingham Heart Study (FHS) participants who attended the ninth examination (2011-2014) in the Offspring cohort were included. This cohort has been described elsewhere. 18, 19 Data were collected during a physician interview, a physical examination and by standard laboratory tests for CVD risk factors. The four-item Morisky Medication Adherence Scale 20 was administered to the 2430 participants who attended the ninth examination. The use of hypertensive, lipid-lowering and/or hypoglycaemic medication(s) was determined by selfreport. After excluding 537 participants who did not report taking at least one of the three studied medications (antihypertensive, lipid-lowering or hypoglycaemic), 245 participants with missing responses to the Morisky Medication Adherence Scale and 89 participants with missing information to covariate assessment(s), a sample, including 1559 participants was available for analysis. The first analysis aimed to study risk factors for low medication adherence. The second analysis studied the associations between medication adherence and CVD risk profiles in 1017 participants taking hypertensive medications, 937 participants taking lipid-lowering medication and 192 participants taking hypoglycaemic medication, with each condition analysed separately. The FHS protocols and procedures were approved by the Institutional Review Board for Human Research at Boston University Medical Center and all participants provided written informed consent.
Medication adherence assessment
Medication adherence was assessed using the four-item Morisky Medication Adherence Scale, which has been used to study adherence for hypertension, 20 diabetes 21, 22 and CVD 23 medications. The four questions included: (i) Did you ever forget to take your medicine? (ii) Are you careless at times about taking your medicine? (iii) When you feel better do you stop taking your medicine? (iv) Sometimes if you feel worse when you take the medicine, do you stop taking it? Response options to these four questions were either yes or no and were assigned the values of 1 or 0 respectively. The values were summed to create an adherence score, ranging from 0 to 4, with higher scores indicating poorer medication adherence. Participants with an adherence score of ≥2 were defined as having low medication adherence, which is consistent with prior studies. 21, 22 
CVD risk factors assessment
At the study examination visit in the FHS research clinic, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) were measured in accordance with standard protocols. 24 SBP and DBP were measured twice by the same physician and the average of the two measurements was used. Hypertension (HTN) was defined as SBP ≥140 mmHg, DBP ≥ 90 mmHg or the use of antihypertensive medication. HTN control was defined as SBP < 140 mmHg and DBP < 90 mmHg among participants with HTN. Low density lipoprotein cholesterol (LDLc) was estimated using the Friedewald equation. 25 LDLc control was defined as LDLc < 100 mg/dL (2.59 mmol/L) if participants had prevalent CVD or Type 2 diabetes or <130 mg/dL (3.36 mmol/L) otherwise.
Anthropometry and covariate assessment
Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). Participants who reported that they smoked regularly (on average one cigarette or more per day) in the past year were categorised as current smokers. Alcohol consumption was estimated by self-reported intake of beer, wine, liquor and spirits. A physical activity score was calculated using responses to a questionnaire on the intensity of and time spent performing physical activity per day. 26 Employment status (employed, self-employed or retired from usual occupation vs unemployed or laid off ) and marital status (married, living as married or living with partner vs single, never married, separated, divorced or widowed) were derived from a standard questionnaire. The Mini-Mental State Examination (MMSE), a brief dementia-screening questionnaire, was implemented to assess participants' cognitive function. 27 The MMSE, which has a maximum score of 30, included 16 individual questions to assess functions for orientation, registration, attention and calculation, recall and language and praxis. The Center for Epidemiologic Studies of Depression (CES-D) scale was administered to assess depressive symptoms. 28 The CES-D scale, ranging from 0 to 60, consisted of 20 items evaluating depressive affect, somatic complaints, positive affect and interpersonal relations.
Statistical analysis
The characteristics of participants were calculated by level of adherence, low (adherence score ≥ 2) or high (score < 2) and compared using Student t-test or Chisquared test. To assess factors associated with low medication adherence, a multiple regression model was implemented with the outcome of low medication adherence. Factors examined included sex, age, BMI, alcohol consumption, current smoking status, physical activity score, employment status, marital status, MMSE score and CES-D score.
Two models were used to examine the associations between low medication adherence and CVD risk factors for each of the self-reported medication groups (antihypertensive, lipid-lowering and hypoglycaemia, separately). Covariates in model 1 were sex and age, while model 2 adjusted for sex, age and variables that were significant in the above analysis for risk factors of low medication adherence. Among participants who reported taking antihypertensive medication, the associations between medication adherence and SBP, DBP and HTN control were analysed. In participants who reported taking lipid-lowering medication, the associations between medication adherence and LDLc and LDLc control were analysed. In participants who reported taking hypoglycaemic medication, the associations between medication adherence and FPG, HbA1c and diabetes control were analysed. Multivariable-adjusted linear regression models were used for continuous outcomes, while Poisson regression models with robust standard errors were used to calculate relative risk (RR) for dichotomised disease control as the prevalence was high. 29 A secondary analysis was conducted to examine whether age modified the observed association between medication adherence and CVD risk factors. A crossproduct term of age (≤70 years or >70 years) and medication adherence was included in the fully adjusted model. An age of 70 years was chosen as it was the median age of the overall study sample. All statistical analyses were conducted using SAS statistical software (version 9.3; SAS Institute, Cary, NC, USA). A two-tailed P < 0.05 value was considered statistically significant.
Results
Participant characteristics
Among the 1559 participants (median age 70 years, 53% women) with complete responses to the Morisky Medication Adherence Scale and covariate assessments, 695 (45%) participants reported that they had forgotten to take medicine; 158 (10%) participants reported that they had been careless at times about taking medicine; 45 (3%) participants reported that they had stopped taking medicine when they felt better and 116 (7%) participants reported that they had stopped taking medicine when they felt worse. Overall, 191 (12%) participants had low medication adherence, defined as adherence score ≥ 2. Among the participants in the low medication adherence group, 181 (95%) reported that they had forgotten to take medicine; 136 (71%) reported that they had been careless at times about taking medicine; 31 (16%) reported that they had stopped taking medicine when they felt better and 73 (38%) reported that they had stopped taking medicine when they felt worse. The prevalence of myocardial infarction and stroke was similar in participants with low medication adherence compared with those with better adherence, 8.4% (n = 16) vs 8.0% (n = 175). Participants with low medication adherence had a higher CES-D score (Table 1 ; P < 0.001).
Potential risk factors for low medication adherence
As presented in Table 2 increased likelihood of low medication adherence; the odds ratio (OR) for having an adherence score ≥ 2 was 1.44 (95% CI: 1.23-1.67, P < 0.001) for every five-unit increase in CES-D score after adjustment for multiple covariates ( Table 2) .
In a post hoc analysis, we categorised participants by CES-D score using cut-off values of 16 and 22. We employed a multiple regression analysis that adjusted for all other potential risk factors shown in Table 2 . We observed a dose-response relationship between CES-D score and medication adherence. Using participants with a CES-D score below 16 as reference, the OR of low medication adherence was 1.29 (95% CI: 0.91, 1.85) in participants who had a CES-D score of 16-21, while the OR of low medication adherence was 3.03 (95% CI: 1.94, 4.73) in participants who had a CES-D of 22 or above (indicating more severe depression), P-trend < 0.001.
Participants taking antihypertensive medication (n = 1017)
Compared with participants who had high medication adherence (n = 918, 90%), those with low medication adherence (n = 99, 10%) had higher DBP after adjustment for sex, age and CES-D score (73 mmHg, 95% CI: 71-75 vs 71 mmHg, 95% CI: 70-71; P = 0.04) ( Table 3 , top panel). No association was present between medication adherence and SBP or medication adherence and HTN control (Table 3 , top panel).
Participants taking lipid-lowering medication (n = 937)
Compared with participants who had high medication adherence (n = 825, 88%), those with low medication adherence (n = 112, 12%) had higher LDLc (92 mg/dL, 95% CI: 87-96 vs 86 mg/dL, 95% CI: 84-88; P = 0.03), after adjustment for sex, age and CES-D score (Table 3 , middle panel). Participants with low medication adherence were also 11% more likely to have uncontrolled LDLc levels compared to their counterparts in the high medication adherence group (RR: 1.11, 95% CI: 1.02-1.22; P = 0.02) ( Table 3 , middle panel).
Participants taking hypoglycaemic medication (n = 192)
Compared with the high medication adherence group (n = 169, 88%), participants with low medication adherence (n = 23, 12%) showed no statistically significant differences in FPG, HbA1c or diabetes control (Table 3 , bottom panel).
Secondary analysis
Age-specific analyses for the association between adherence and cardiovascular risk factors and disease control are presented in Tables S1 and S2 (Supporting Information) respectively. The P-value for interaction between age and medication adherence was greater than 0.05 for all outcomes except LDLc control and FPG. High adherence was associated with lower LDLc and LDLc control among participants ≤70 years, but not among those >70 years (P-interaction = 0.007; Table S2 , middle panel). Additionally, the P-interaction was 0.05 for FPG (Table S1 , bottom panel); however, there was no statistically significant association between medication adherence and FPG levels in either age group.
Discussion Principal findings
Among older adults in the current analysis, 12% were categorised as having low medication adherence. A higher CES-D score (i.e. more depressive symptoms) was associated with low medication adherence. Furthermore, low adherence was associated with higher DBP in participants using antihypertensive medication and higher and uncontrolled LDLc in participants using lipid-lowering medications.
In the context of the current literature
The prevalence of low medication adherence in our study sample (12%) is lower compared to several other cohort studies. 16 Nevertheless, our findings are in line with many studies, which have shown that low medication adherence may hinder the effectiveness of treatment for various conditions. [8] [9] [10] [11] [12] [13] [14] 30, 31 For example, low medication adherence is one of the key risk factors for poor hypertension control, 16 and may account for up to half of resistant hypertension cases. 30 CoSMO, including 2194 adults with hypertension, assessed the determinants of medication adherence using the medication possession ratio and a validated self-report adherence scale. The analyses showed that adherence, measured by both metrics, was associated with uncontrolled blood pressure. 16 It should be noted that high SBP is particularly prevalent among adults in FHS, 32 which might have decreased the power for the association between SBP and medication adherence. Additionally, a retrospective cohort study of 1066 patients receiving statin medication found that the risk of not achieving the LDLc reduction goal in patients who had intermediate and low adherence increased by 31% and 88% respectively compared with those with high adherence. 33 Although the present study did not find an association between medication adherence and glycaemic control, potentially due to the small sample size of participants using hypoglycaemic medication (n = 192), other studies have reported an association. In a systematic review of adherence and glycaemic control determined by HbA1c, there was a direct association between low medication adherence, which was assessed by self-report and pharmacy fills, and worse glycaemic control. 12 Many intervention studies have been designed, but failed to improve either medication adherence or associated clinical outcomes through improvements in adherence.
14 Interventions specifically designed to improve medication adherence barriers in individuals at-risk for poor adherence could lead to better clinical outcomes. 6, 15 For example, the observation from the present study that a higher CES-D score could constitute a barrier for adherence is consistent with other studies. 12, [34] [35] [36] [37] [38] [39] To target depression as a barrier to medication adherence for comorbid conditions, studies have analysed the extent to which integrated care could be effective in treating both disease outcomes. A randomised trial in 64 individuals with hypertension and depression showed that integrated care, focused on treating hypertension and depression simultaneously, improved adherence to antihypertensive medications and resulted in lower blood pressure. 40 However, a randomised controlled trial that examined individual cognitive therapies in 94 outpatients with diabetes and comorbid depression found that glycaemic control was not improved even though depressive symptoms were reduced. 41 Thus, future intervention studies tailored to older adults with depression and CVD are warranted to improve medication adherence and clinical outcomes.
It should be noted that other factors in addition to depression may be barriers to achieving high medication adherence. As shown in the present analyses, adjustment for depressive symptoms did not substantially change the association between low medication adherence and increased CVD risk. Cognitive impairment and memory may have a role in medication adherence among the elderly. MMSE score ceiling effects resulted in no statistically significant association between cognitive functioning and low medication adherence in the present study. The MMSE alone may not be effective in diagnosing mild cognitive impairment. 42 Nevertheless, a small pre-post intervention study found that reminder devices improved medication adherence in older adults with mild cognitive impairment. 43 Thus, additional welldesigned studies with larger sample sizes are needed to identify the role of cognitive decline in medication adherence, as well as the relationship between reduction of these factors and control of chronic diseases in the elderly population. 17 
Implications
Many studies have shown that medication adherence is an important factor associated with CVD risk. 8, 14 Although, the observed association is relatively weak, our findings do support that improving medication adherence may benefit control for CVD risk factors. This is particularly important for the elderly population since older adults constitute a high-risk population for poor medication adherence due to decreased cognitive function. The finding that depressive symptoms may act as a risk factor for medication non-adherence in older adults should be considered in future intervention studies and clinical practice.
Strengths and limitations
This study used the comprehensive data collected from FHS, which has been a hallmark in identifying CVD risk factors among free-living adults. 44 However, due to the observational and cross-sectional nature of this study and relatively weak observed association between medication adherence and CVD risk factors, a causal relationship could not be ascertained. No gold standard definition exists for long-term medication adherence. 45 Defining low medication adherence as two or more positive responses to the Morisky Medication Adherence Scale is somewhat arbitrary and primarily focuses on participants' attitudes toward their medications rather than their behaviours. The self-reported questionnaire also has the potential to introduce response bias into the study. In addition, the Morisky Medication Adherence Scale does not assess other factors that may contribute to low medication adherence, such as the general healthcare system. 46 We could not validate medication adherence assessed by the questionnaire with medication possession ratios or provider data in our study sample. Furthermore, since only one medication adherence questionnaire was implemented, we cannot test the association of current CES-D score to remote medication adherence. The use of MMSE to measure cognitive functioning might not have been sufficient to identify those with mild cognitive impairment, especially because previous studies have found that cognitive impairment significantly impacts medication adherence. secondary age interaction analyses were also limited due to the small subgroup sample sizes. Finally, all study participants were Caucasian, which may limit the generalisability to populations of different racial and/or ethnic backgrounds.
Conclusion
Low medication adherence was associated with adverse CVD risk profiles, including uncontrolled LDLc and higher DBP and LDLc, in a group of older adults in the community. Having more depressive symptoms was associated with low medication adherence. Future intervention studies are warranted to examine if integrating care for depression and CVD risk factors could improve medication adherence and clinical outcomes in the elderly.
